The study found that Prequel ® Prenatal Screen with AMPLIFY™ technology enables reliable results as early as eight-weeks’ gestation. Typically, prenatal cell-free DNA (pcfDNA) screening is offered ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at ...

As the world continues to adapt to digital transformation with a myriad of technology use cases and ‘everything-as-a-service’ ...

January 20, 2025) - Myriad Uranium Corp. (CSE: M) (OTCQB: MYRUF) (FSE: C3Q) ("Myriad" or the "Company") is pleased to announce an expansion of the Copper Mountain Project Area, from approximately ...

For most fans, the behind-the-scenes crisis PR machine that mitigates the public narratives of ... Us,” amplifying a hate narrative that in turn caught the attention of myriad news sites, including ...

The study is the first publication to emerge from the company's ongoing prospective study, Myriad Augmented Soft Tissue Reconstruction Registry (MASTRR). The study found that AROA's Myriad Matrix™ and ...

The study found that AROA’s Myriad Matrix™ and Myriad Morcells™ achieved successful ... [3] AROA Management estimates This article was produced by Cision PR Newswire, our trusted news partner. The ...

Myriad Genetics, Inc. announced its preliminary financial results for the fourth quarter and full year of 2024, projecting total revenues of $209 million to $211 million for Q4 and $836 million to ...

SALT LAKE CITY, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced select unaudited preliminary results for ...